ResMed
United States · Health Care, Medical Device, Mobile
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and ca
Key facts
- Headquarters
- United States
- Employees
- 10,000
- Industries
- Health Care, Medical Device, Mobile
- Status
- Public (RMD)
- Website
- resmed.com
- Company page
Recent activity at ResMed
- : SEC 8-K (8.01): On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement (ASR Agreement) with Citibank, N.A. to repurchase $450.0 million worth of its common stock. This action is part of a broader repurchase authorization for 20 million shares approved by the board in February 2014. The funding for this repurchase will come from the proceeds of the recent sale of its MatrixCare business and existing cash reserves. Under the terms of the ASR Agreement, ResMed will pay Citibank $450.0 million on September 3, 2026, in return for an initial delivery of shares representing 80% of the repurchase amount based on the stock's closing price on September 2, 2026. This buyback aligns with the fiscal guidance provided by the company during the Q4 FY26 earnings call on August 6, 2026.
- : ResMed Inc. Initiates $450 Million Accelerated Share Repurchase
- : ResMed acquires Noctrix Health for $340 million
- : ResMed partners with Oura to integrate consumer sleep insights with clinical care pathways.
- : SEC 8-K (5.02): On November 19, 2025, Richard Sulpizio did not seek re-election at the Annual Meeting, resulting in the expiration of his term and creating a vacancy on ResMed Inc.'s board of directors. Consequently, the board approved a reduction of the number of directors from twelve to eleven. This change reflects a strategic adjustment within the company's governance as it moves forward without Sulpizio. Additionally, during the same meeting, stockholders approved an amendment to the ResMed 2009 Incentive Award Plan, increasing the number of shares reserved for issuance under this plan by 2,400,000, which is significant for potential employee compensation and retention strategies.
- : Cerracap Ventures Celebrates Successful Exit As Resmed Acquires Portfolio Company Somnoware Healthcare Systems Inc.
- : Resmed Acquires Somnoware, A Leader In Digital Sleep And Respiratory Care Diagnostics Software
- : Resmed Completes Acquisition Of Medifox Dan, A German Leader In Out-Of-Hospital Care Management Software Solutions
- : Resmed To Acquire Medifox Dan, A German Leader In Out-Of-Hospital Software Solutions
ResMed funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Funding Round | $450.0M |
Leadership
- VJ, Vice President, Marketing Partnerships & Growth
- Rishabh Singh, Senior Talent Acquisition Partner
- Lekha Singh, Senior Talent Acquisition Partner -APAC & EU
- Aaron Bloomer, Chief Financial Officer
- Rob Douglas, Chief Operating Officer
Verified email and direct lines for ResMed’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
ResMed files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
ResMed in the news
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 - www.marketscreener.com (Oct 01, 2026)
- Resmed ventilator safety issue linked to 5 serious injuries - MedTech Dive (Jul 20, 2026)
- ResMed snaps up Noctrix Health in $340M sleep tech deal - Fierce Biotech (Jun 08, 2026)
- Resmed, Oura partner on sleep health education, care - MassDevice (May 19, 2026)
- Resmed integrating AI for sleep apnea treatment - Fox Business (May 05, 2026)
- The Strategic Integration of Neuromodulation in Sleep Medicine: An Analysis of ResMed’s Acquisition of Noctrix Health - www.healthcare.digital (May 11, 2026)
- Frazier Healthcare Buys Resmed's MatrixCare in $490M Deal - Medical Device and Diagnostic industry (Jul 08, 2026)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD - PR Newswire (Sep 03, 2026)
Companies similar to ResMed
- OrthoPediatrics · Health Care, Medical Device, Mobile
- League · Health Care, Mobile, Sports
- Valera Health · Health Care, Mobile, Sports
- Bardavon Health Innovations, Inc. · Health Care, Mobile, Sports
- CloudMD Software & Services · Health Care, Mobile, Sports
About ResMed: questions and answers
What does ResMed do?
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and ca
Where is ResMed headquartered?
ResMed is headquartered in United States.
How many employees does ResMed have?
ResMed has about 10,000 employees.
Has ResMed raised funding?
Yes. Fundz has recorded 1 funding event for ResMed. The most recent, Funding Round of $450.0M, was in Aug 2026.
Who leads ResMed?
VJ is a Vice President, Marketing Partnerships & Growth at ResMed.
What is the latest news on ResMed?
On Aug 31, 2026, SEC 8-K (8.01): On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement (ASR Agreement) with Citibank, N.A. to repurchase $450.0 million worth of its common stock. This action is part of a broader repurchase authorization for 20 million shares approved by the board in
Is ResMed a public company?
Yes. ResMed is publicly traded under the ticker RMD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy